Jaguar Health 's Napo Pharmaceuticals Announces Activation By FDA Of Investigational New Drug (IND) Application For Crofelemer For Treatment Of Microvillus Inclusion Disease
Portfolio Pulse from Benzinga Newsdesk
Jaguar Health's subsidiary, Napo Pharmaceuticals, has received activation from the FDA for its Investigational New Drug (IND) application for Crofelemer, a treatment for Microvillus Inclusion Disease.
August 08, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jaguar Health's stock may see positive movement due to the FDA's activation of the IND application for Crofelemer, a drug developed by its subsidiary, Napo Pharmaceuticals.
The FDA's activation of the IND application for Crofelemer is a significant regulatory milestone for Jaguar Health and its subsidiary, Napo Pharmaceuticals. This could potentially lead to increased investor confidence and a positive impact on Jaguar Health's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100